Beyond α-Synuclein SAA: A Multimodal Minimally Invasive Platform for Biologically Informed Diagnosis of Parkinsonian Syndromes
Objective: To evaluate whether integrating dermal α-synuclein and 4R-tau seed amplification assays (SAAs) with serum neurofilament light chain (NfL) improves diagnostic precision in neurodegenerative parkinsonian…Pain Management in Parkinson’s Disease: The Role of TRPV1 as a Therapeutic Target
Objective: Parkinson’s Disease (PD) is the second most common neurodegenerative disorder. Pain is one of the most prevalent non-motor symptoms in PD, impacting health-related quality…Synuclein and dopamine transporter biomarkers among phenoconverters to parkinsonian disorders
Objective: To describe and assess biological congruency, defined as expected biological profile based on abnormal CSF α-synuclein Seed Amplification Assays (CSFaSynSAA) and dopamine transporter SPECT…18F-FD4 PET Reveals α-Synuclein Deposition and Clinical Correlations in Parkinson’s Disease
Objective: This study aimed to determine the potential of a novel α-syn tracer, 18F-FD4 PET, to track regional α-synuclein deposition in PD and explore its…Alpha-synuclein Seed Amplification Assay Set Up: Quality Control Using Standards and Controls
Objective: To evaluate the use of standards and controls in alpha-synuclein seed amplification assays (ɑ-syn SAAs). Background: Alpha-synuclein SAAs show great promise for the diagnosis…A Randomized, Double-blind Phase 3 Trial of Amlenetug Versus Placebo in Patients with MSA: The MASCOT Trial
Objective: Describe the protocol for a randomized, double-blind phase 3 trial evaluating the efficacy and safety of amlenetug versus placebo in slowing clinical progression in…Correlations of catecholamine metabolites and alpha-synuclein by nigral stimulation in Parkinson’s disease model rat
Objective: We aimed to clarify the effects of substantia nigra (SN) stimulation on catecholamine levels and α-synuclein in PD model rats. Background: Catecholaminergic neurons are…Platelets Lipidome as Potential Biomarker of Parkinson’s Disease
Objective: The aim of this proejct is to identify novel biomarkers of Parkinson's disease diagnosis and progression, with a focus on GBA-PD. Background: Our previous…Validation of CSF Alpha-synuclein SAA in an Autopsy Cohort with Systemic Assessment of Lewy Pathology Including the Body
Objective: Based on the recent recommendations by international neuropathologists [1], we attempted to evaluate the diagnostic accuracy of cerebrospinal fluid (CSF) alpha-synuclein (α-syn) seeding amplification…Rescuing alpha-synuclein toxicity through neuron-specific enhancement of autophagy
Objective: In the present study, we aim to counteract regulatory and transcriptional modifiers of autophagy to enhance neuroprotective proteostasis and rescue alpha-synuclein (asyn) toxicity in…
- « Previous Page
- 1
- …
- 8
- 9
- 10
- 11
- 12
- …
- 70
- Next Page »